Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1161-1180 of 1,307 trials

Lung Cancer Treatment: Rilvegostomig vs. Pembrolizumab

We are studying a new drug, rilvegostomig, to see if it works better than pembrolizumab for patients with PD-L1-high metastatic non-small cell lung cancer. This trial aims to understand which treatment may improve survival and quality of life.

Lung CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sacubitril/Valsartan for Heart Protection in Breast Cancer Treatment

We are studying whether sacubitril/valsartan can help prevent heart damage in women receiving systemic treatment for breast cancer. This trial aims to understand its potential benefits in protecting heart function during therapy.

Heart Failure>2 yearsConfirmation phase (III)Investigational MedicinesCardiologyOncology

Graves' Ophthalmopathy: Diclofenac vs. Simvastatin

We are studying whether diclofenac or simvastatin can help patients with mild to moderate Graves' ophthalmopathy. The trial aims to assess the activity of the disease and its progression to more severe forms.

Graves' Ophthalmopathy6-12 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesEndocrinologyOphthalmology

DAVINCY Trial: (fos)Aprepitant for Nausea in Children

We are studying whether a longer duration of (fos)aprepitant can better prevent nausea and vomiting in children receiving chemotherapy. This trial compares the standard treatment with an extended regimen to find the most effective approach.

Delayed Chemotherapy Induced Nausea and VomitingConfirmation phase (III)Investigational MedicinesPartially RemoteInternal MedicineOncologyPediatrics

Prostate Cancer: Atorvastatin Study

We are investigating whether atorvastatin can help delay prostate cancer progression in men receiving androgen deprivation therapy. This study aims to see if it can prevent the cancer from becoming resistant to treatment.

Metastatic Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesOncologyUrology

ADPKD Treatment: Metformin vs. Tolvaptan

We are studying whether Metformin can effectively slow kidney function decline in adults with Autosomal Dominant Polycystic Kidney Disease compared to Tolvaptan. The trial also examines the safety and impact on kidney size and symptoms.

Autosomal Dominant Polycystic Kidney Disease>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Hydrocortisone Treatment in Pancreatoduodenectomy Surgery

We are studying whether hydrocortisone infusions can help reduce complications after pancreatoduodenectomy surgery. This trial compares the effects of hydrocortisone to a placebo in patients undergoing this procedure.

Pancreatic Resection>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Nephrotic Syndrome: Ketoanalogues for Muscle Preservation

We are studying a new treatment to help prevent muscle loss in patients with nephrotic syndrome. This trial will assess its safety and how it may improve overall health and quality of life.

Protein-Energy Wasting in Nephrotic Syndrome>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Long COVID: Fibroblast Activity Study with [68Ga]FAPI PET/CT

We are investigating if patients with ongoing long COVID symptoms have higher fibroblast activity than those who have recovered. This may help us understand the underlying causes of long-term health issues after COVID-19.

Long COVIDConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Cardiac AL Amyloidosis: PET/CT Imaging Study

We are studying a new non-invasive imaging method to diagnose cardiac AL amyloidosis in patients with a specific type of protein in their blood. This research aims to see if this method is as effective as traditional invasive tests.

Cardiac Amyloidosis1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Non-Small Cell Lung Cancer: Sigvotatug Vedotin with Pembrolizumab

We are studying a new treatment combining sigvotatug vedotin with pembrolizumab for patients with advanced non-small cell lung cancer that has high PD-L1 levels. The goal is to see if this combination works better than pembrolizumab alone.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Warm Autoimmune Hemolytic Anemia: Rilzabrutinib Study

We are investigating whether the oral medication rilzabrutinib can improve hemoglobin levels and reduce symptoms in adults with warm autoimmune hemolytic anemia. This study will also assess its safety compared to a placebo.

Autoimmune Hemolytic Anemia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesHematologyInternal Medicine

Chronic Migraine: CGRP Monoclonal Antibody and Botox Combination Therapy

We are investigating whether a combination of CGRP monoclonal antibodies and Botox can reduce the number of migraine days for adults with chronic migraines. This study compares the effects of this dual therapy to a single treatment with CGRP monoclonal antibodies.

Chronic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Ozone Therapy for Chemotherapy-Induced Pain Relief

We are studying whether adding ozone therapy helps cancer patients with painful neuropathy feel better and improve their quality of life. This trial will also look at the costs and safety of this treatment.

Chemotherapy-Induced Peripheral Neuropathy3-6 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesNeurologyOncology

Orthopedic Surgery: Intraoperative Methadone Study

We are investigating whether methadone can reduce pain and improve satisfaction after orthopedic surgery compared to standard pain relief methods. This study aims to ensure safety while managing postoperative pain effectively.

Orthopedic Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOrthopedics and Traumatology

Locally Advanced Rectal Cancer: FOLFOX Before Surgery

We are comparing the effects of chemotherapy before surgery to risk-adapted chemotherapy after surgery for patients with locally advanced rectal cancer. Our goal is to see which approach may lead to better disease-free survival and fewer complications.

Locally Advanced Rectal Cancer≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Lung Cancer: RMC-6236 vs. Docetaxel

We are studying a new treatment for patients with advanced lung cancer who have RAS mutations. The goal is to see if RMC-6236 works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Moderate Atopic Dermatitis: Ruxolitinib Cream for Kids

We are studying a new cream for children and adolescents aged 6 to under 18 with moderate atopic dermatitis who haven't had success with other treatments. The trial will assess how well it works and its safety.

Atopic Dermatitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

EGFR-Mutated Lung Cancer: ERIS Study

We are exploring the best sequence of EGFR-inhibitors for patients with EGFR-mutated lung cancer. The study also examines treatment effects, side effects, and quality of life.

EGFR-Mutated Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Pancreatic Cancer: Napabucasin with Chemotherapy

We are studying how well Napabucasin works with chemotherapy for patients with metastatic pancreatic cancer after previous treatments have failed. The goal is to see if this combination improves survival and quality of life compared to standard care.

Metastatic Pancreatic CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology